Fusion Proteins: Applications and Challenges

Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges

Volumn , Issue , 2013, Pages 1-24

  Schmidt, Stefan R ^a  

^a Rentschler Biotechnologie GmbH   (Germany)

Author keywords

Fusion proteins; Linker engineering; Mutagenesis; Patenting manufacturing; Regulatory challenges

Indexed keywords

EID: 84886220373     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118354599.ch1     Document Type: Chapter

References (172)

1. Cohn EJ, Oncley JL, Strong LE, Hughes WL, Armstrong SH. (1944) Chemical, clinical, and immunological studies on the products of human plasma fractionation. I. The characterization of the protein fractions of human plasma. J. Clin. Invest. 23, 417-432.
2. Krauss J, Arndt MAE, Vu BK, Newton DL, Rybak SM. (2005) Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme. Br. J. Haematol. 128(5), 602-609.
3. Goeddel DV, Kleid DG, Bolivar F, Heyneker HL, Yansura DG, Crea R, et al. (1979) Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc. Natl. Acad. Sci. USA 76(1), 106-110.
4. Kohler G, Milstein C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (5517), 495-497.
5. Kempeni J. (1999) Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7. Ann. Rheum. Dis. 58(Suppl. 1), I70-72.
6. Peppel K, Crawford D, Beutler B. (1991) A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J. Exp. Med. 174(6), 1483-1489.
7. Cai Q, Peng G, Bu L, Lin Y, Zhang L, Lustigmen S, et al. (2007) Immunogenicity and in vitro protective efficacy of a polyepitope plasmodium falciparum candidate vaccine constructed by epitope shuffling. Vaccine 25(28), 5155-5165.
8. Teicher BA, Chari RVJ. (2011) Antibody conjugate therapeutics: challenges and potential. Clin. Cancer Res. 17(20), 6389-6397.
9. Edwards PAW. (2010) Fusion genes and chromosome translocations in the common epithelial cancers. J. Pathol. 220(2), 244-254.
10. Terpe K. (2003) Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems. Appl. Microbiol. Biotechnol. 60(5), 523-533.
11. Schmidt SR. (2009) Fusion-proteins as biopharmaceuticals: applications and challenges. Curr. Opin. Drug Discov. Dev. 12(2), 284-295.
12. Leader B, Baca QJ, Golan DE. (2008) Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 7(1), 21-39.
13. Gebauer M, Skerra A. (2009) Engineered protein scaffolds as next-generation antibody therapeutics. Curr. Opin. Chem. Biol. 13(3), 245-255.
14. Schmidt S.R. (2008) Fusion-Proteins as Biopharmaceuticals: Applications and Challenges. Protein Expression Europe & Antibodies Europe. Lisbon, Portugal, 20-23 October.
15. Schellekens H. (2004) When biotech proteins go off-patent. Trends Biotechnol. 22(8), 406-410.
16. Webber PM. (2007) The patenting of novel biotech products. IDrugs 10(7), 459-462.
17. Ilag LL, Ilag LM, Ilag LL. (2002) From patenting genes to proteins: the search for utility via function. Trends Biotechnol. 20(5), 197-199.
18. Webber P. (2006) Patenting antibodies. Nat. Rev. Drug Discov. 5(2), 97.
19. Hashimoto K, Aida T. (2008) Antibody patenting without antibodies: a global trend. Nat. Biotechnol. 26(12), 1341-1343.
20. Holliday L. (2009) Patenting antibodies in Europe. MAbs 1 (4), 385-386.
21. Bachran C, Sutherland M, Bachran D, Fuchs H. (2007) Patents on immunotoxins and chimeric toxins for the treatment of cancer. Recent Pat. Drug Deliv. Formul. 1(2), 105-115.
22. McCabeKW. (2009) Guardians at the gate: patent protection for therapeutic monoclonal antibodies (Part 1). MAbs 1, 382-384.
23. Agris CH. (1998) Patenting protein sequences. Nat. Biotech. 16(11), 1075.
24. Dorey E. (2010) Bristol-Myers Squibb reaps biologics in ZymoGenetics windfall. Nat. Biotech. 28, 1137-1138.
25. Marshall SA, Lazar GA, Chirino AJ, Desjarlais JR. (2003) Rational design and engineering of therapeutic proteins. Drug Discov. Today 8(5), 212-221.
26. Cuesta AM, Sainz-Pastor N, Bonet J, Oliva B, Alvarez- Vallina L. (2010) Multivalent antibodies: when design surpasses evolution. Trends Biotechnol. 28(7), 355-362.
27. Ortiz-Sanchez E, Helguera G, Daniels TR, Penichet ML. (2008) Antibody-cytokine fusion proteins: applications in cancer therapy. Expert Opin. Biol. Ther. 8, 609-632.
28. Oliner J, Min H, Leal J, Yu D, Rao S, You E, et al. (2004) Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cells 6(5), 507-516.
29. Evans L, Hughes M, Waters J, Cameron J, Dodsworth N, Tooth D, et al. (2010) The production, characterisation and enhanced pharmacokinetics of scFv-albumin fusions expressed in Saccharomyces cerevisiae. Protein Expr. Purif. 73(2), 113-124.
30. Zhao HL, Xue C, Wang Y, Li XY, Xiong XH, Yao XQ, et al. (2007) Circumventing the heterogeneity and instability of human serum albumin-interferon-alpha2b fusion protein by altering its orientation. J. Biotechnol. 131(3), 245-252.
31. Paek S-Y, Kim Y-S, Choi S-G. (2010) The orientationdependent expression of angiostatin-endostatin hybrid proteins and their characterization for the synergistic effects of antiangiogenesis. J. Microbiol. Biotechnol. 20(10), 1430-1435.
32. Christensen T, Amiram M, Dagher S, Trabbic-Carlson K, Shamji MF, Setton LA, et al. (2009) Fusion order controls expression level and activity of elastin-like polypeptide fusion proteins. Protein Sci. 18(7), 1377-1387.
33. Arndt MAE, Krauss J, Vu BK, Newton DL, Rybak SM. (2005) A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cells. J. Immunother. 28(3), 245-251.
34. Mariuzza RA, Poljak RJ, Mihaesco C, Mihaesco E. (1983) Crystals of the human heavy chain disease protein Riv and human Fc fragment are isomorphous: further evidence for conformational flexibility in the hinge region of immunoglobulins. J. Mol. Biol. 165(3), 559-561.
35. Wriggers W, Chakravarty S, Jennings PA. (2005) Control of protein functional dynamics by peptide linkers. Biopolymers 80(6), 736-746.
36. Argos P. (1990) An investigation of oligopeptides linking domains in protein tertiary structures and possible candidates for general gene fusion. J. Mol. Biol. 211(4), 943-958.
37. Newton DL, Xue Y, Olson KA, Fett JW, Rybak SM. (1996) Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains. Biochemistry 35(2), 545-553.
38. Arai R, Ueda H, Kitayama A, Kamiya N, Nagamune T. (2001) Design of the linkers which effectively separate domains of a bifunctional fusion protein. Protein Eng. 14(8), 529-532.
39. Zhao HL, Yao XQ, Xue C, Wang Y, Xiong XH, Liu ZM. (2008) Increasing the homogeneity, stability and activity of human serum albumin and interferon-alpha2b fusion protein by linker engineering. Protein Expr. Purif. 61(1), 73-77.
40. Xue F, Gu Z, Feng J. (2004) LINKER: a web server to generate peptide sequences with extended conformation. Nucleic Acids Res. 32(Web Server issue), W562-W565.
41. George RA, Heringa J. (2002) An analysis of protein domain linkers: their classification and role in protein folding. Protein Eng. 15(11), 871-879.
42. Chen X, Bai Y, Zaro JL, Shen W-C. (2010) Design of an in vivo cleavable disulfide linker in recombinant fusion proteins. BioTechniques 49(1), 513-518.
43. Bai Y, Shen W-C. (2006) Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization. Pharm. Res. 23(9), 2116-2121.
44. Amet N, Lee H-F, ShenW-C. (2009) Insertion of the designed helical linker led to increased expression of tf-based fusion proteins. Pharm. Res. 26(3), 523-528.
45. Goyal A, Batra JK. (2000) Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins. Biochem. J. 345(Pt 2), 247-254.
46. Chen T, Yang J, Wang Y, Zhan C, Zang Y, Qin J. (2005) Design of recombinant stem cell factor-macrophage colony stimulating factor fusion proteins and their biological activity in vitro. J. Comput. Aided Mol. Des. 19(5), 319-328.
47. Won J, Nam P, Lee Y, Choe M. (2009) Higher cytotoxicity of divalent antibody-toxins than monovalent antibody-toxins. Biochem. Biophys. Res. Commun. 382(1), 15-20.
48. Liu M,Wang X, Yin C, Zhang Z, Lin Q, Zhen Y, et al. (2008) A novel bivalent single-chain variable fragment (scFV) inhibits the action of tumour necrosis factor a. Biotechnol. Appl. Biochem. 50(4), 173.
49. de Kruif J, Logtenberg T. (1996) Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library. J. Biol. Chem. 271(13), 7630-7634.
50. Hoyne PA, Cosgrove LJ, McKern NM, Bentley JD, Ivancic N, Elleman TC, et al. (2000) High affinity insulin binding by soluble insulin receptor extracellular domain fused to a leucine zipper. FEBS Lett. 479(1-2), 15-18.
51. Morris NP, Peters C, Montler R, Hu H-M, Curti BD, Urba WJ, et al. (2007) Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol. Immunol. 44(12), 3112-3121.
52. Rozanov DV, Savinov AY, Golubkov VS, Rozanova OL, Postnova TI, Sergienko EA, et al. (2009) Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells. Mol. Cancer Ther. 8(6), 1515-1525.
53. Spitzer D, McDunn JE, Plambeck-Suess S, Goedegebuure PS, Hotchkiss RS, Hawkins WG. (2010) A genetically encoded multifunctional TRAIL trimer facilitates cellspecific targeting and tumor cell killing. Mol. Cancer Ther. 9(7), 2142-2151.
54. Krippner-Heidenreich A, Grunwald I, Zimmermann G, Kuhnle M, Gerspach J, Sterns T, et al. (2008) Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity. J. Immunol. 180(12), 8176-8183.
55. Berg D, Lehne M, Muller N, Siegmund D, Munkel S, Sebald W, et al. (2007) Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ. 14(12), 2021-2034.
56. Stone GW, Barzee S, Snarsky V, Kee K, Spina CA, Yu X-F, et al. (2006) Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J. Virol. 80(4), 1762-1772.
57. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, et al. (2003) Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol. Cell. Biol. 23(4), 1428-1440.
58. Sanchez-Arevalo Lobo VJ, Cuesta AM, Sanz L, Compte M, Garcia P, Prieto J, et al. (2006) Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events. Int. J. Cancer 119(2), 455-462.
59. Fan C-Y, Huang C-C, ChiuW-C, Lai C-C, Liou G-G, Li H-C, et al. (2008) Production of multivalent protein binders using a self-trimerizing collagen-like peptide scaffold. FASEB J. 22 (11), 3795-3804.
60. Rohn J. (2010) Newsmaker: anaphore. Nat. Biotechnol. 28(11), 1143.
61. Onda M, Beers R, Xiang L, Nagata S, Wang Q-C, Pastan I. (2008) An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc. Natl. Acad. Sci. USA 105(32), 11311-11316.
62. Pastan I, Onda M, Weldon J, Fitzgerald D, Kreitman R. (2011) Immunotoxins with decreased immunogenicity and improved activity. Leuk. Lymphoma 52(Suppl. 2), 87-90.
63. Harding FA, Liu AD, Stickler M, Razo OJ, Chin R, Faravashi N, et al. (2005) A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. Mol. Cancer Ther. 4(11), 1791-1800.
64. Liang Y, Qiu H, Glinka Y, Lazarus AH, Ni H, Prud'homme GJ, et al. (2011) Immunity against a therapeutic xenoprotein/ Fc construct delivered by gene transfer is reduced through binding to the inhibitory receptor FcgRIIb. J. Gene Med. 13(9), 470-477.
65. De Groot AS, Scott DW. (2007) Immunogenicity of protein therapeutics. Trends Immunol. 28(11), 482-490.
66. Onda M. (2009) Reducing the immunogenicity of protein therapeutics. Curr. Drug Targets 10(2), 131-139.
67. Brinkmann U, Pai LH, FitzGerald DJ, Pastan I. (1992) Alteration of a protease-sensitive region of Pseudomonas exotoxin prolongs its survival in the circulation of mice. Proc. Natl. Acad. Sci. USA 89(7), 3065-3069.
68. Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ, et al. (2009) A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 113(16), 3792-3800.
69. Gillies SD, Lo K-M, Burger C, Lan Y, Dahl T, Wong W-K. (2002) Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis. Clin. Cancer Res. 8(1), 210-216.
70. Tcherniuk SO, Chroboczek J, Balakirev MY. (2005) Construction of tumor-specific toxins using ubiquitin fusion technique. Mol. Ther. 11(2), 196-204.
71. Reiter Y, Brinkmann U, Webber KO, Jung SH, Lee B, Pastan I. (1994) Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. Protein Eng. 7(5), 697-704.
72. Way JC, Lauder S, Brunkhorst B, Kong S-M, Qi A, Webster G, et al. (2005) Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond. Protein Eng. Des. Sel. 18(3), 111-118.
73. Liu W, Onda M, Kim C, Xiang L, Weldon JE, Lee B, et al. (2012) A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity. Protein Eng. Des. Sel. 25(1), 1-6.
74. Zhao HL, Xue C, Wang Y, Sun B, Yao XQ, Liu ZM. (2009) Elimination of the free sulfhydryl group in the human serum albumin (HSA) moiety of human interferon-alpha2b and HSA fusion protein increases its stability against mechanical and thermal stresses. Eur. J. Pharm. Biopharm. 72(2), 405-411.
75. Won J, Choe M. (2008) Disulfide bond bridged divalent antibody-toxin, (Fab-PE38fl)2, with the toxin PE38 fused to the light chain. J. Microbiol. Biotechnol. 18(8), 1475-1481.
76. Chowdhury PS, Vasmatzis G, Beers R, Lee B, Pastan I. (1998) Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv. J. Mol. Biol. 281(5), 917-928.
77. McDonagh CF, Beam KS, Wu GJS, Chen JH, Chace DF, Senter PD, et al. (2003) Improved yield and stability of L49- sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering. Bioconjug. Chem. 14(5), 860-869.
78. Narhi LO, Arakawa T, Aoki K, Wen J, Elliott S, Boone T, et al. (2001) Asn to Lys mutations at three sites which are N-glycosylated in the mammalian protein decrease the aggregation of Escherichia coli-derived erythropoietin. Protein Eng. 14(2), 135-140.
79. Dunn CJ, Goa KL. (2001) Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction. Am. J. Cardiovasc. Drugs 1(1), 51-66.
80. Johnson IS. (1983) Human insulin from recombinant DNA technology. Science 219(4585), 632-637.
81. Dingermann T. (2008) Recombinant therapeutic proteins: production platforms and challenges. Biotechnol. J. 3(1), 90-97.
82. Demain AL, Vaishnav P. (2009) Production of recombinant proteins by microbes and higher organisms. Biotechnol. Adv. 27(3), 297-306.
83. Rader RA. (2008) Expression systems for process and product improvement. BioProc. Intl. 6(Suppl. 4), 4-9.
84. Walsh G. (2010) Biopharmaceutical benchmarks 2010. Nat. Biotech. 28(9), 917-924.
85. Sheffield WP, McCurdy TR, Bhakta V. (2005) Fusion to albumin as a means to slow the clearance of small therapeutic proteins using the Pichia pastoris expression system. Therapeutic Proteins, pp. 145-154.
86. Lin H, Kim T, Xiong F, Yang X. (2007) Enhancing the production of Fc fusion protein in fed-batch fermentation of Pichia pastoris by design of experiments. Biotechnol. Prog. 23(3), 621-625.
87. Sørensen HP, Mortensen KK. (2005) Advanced genetic strategies for recombinant protein expression in Escherichia coli. J. Biotechnol. 115(2), 113-128.
88. Kim JY, Kim Y-G, Lee GM. (2012) CHO cells in biotechnology for production of recombinant proteins: current state and further potential. Appl. Microbiol. Biotechnol. 93(3), 917-930.
89. Makrides SC. (1996) Strategies for achieving high-level expression of genes in Escherichia coli. Microbiol. Rev. 60 (3), 512-538.
90. Kamionka M. (2011) Engineering of therapeutic proteins production in Escherichia coli. Curr. Pharm. Biotechnol. 12(2), 268-274.
91. Jana S, Deb JK. (2005) Strategies for efficient production of heterologous proteins in Escherichia coli. Appl. Microbiol. Biotechnol. 67(3), 289-298.
92. Swartz JR. (2001) Advances in Escherichia coli production of therapeutic proteins. Curr. Opin. Biotechnol. 12(2), 195-201.
93. Panda AK. (2003) Bioprocessing of therapeutic proteins from the inclusion bodies of Escherichia coli. Adv. Biochem. Eng. Biotechnol. 85, 43-93.
94. Urieto JO, Liu T, Black JH, Cohen KA, Hall PD,Willingham MC, et al. (2004) Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expr. Purif. 33(1), 123-133.
95. Woo JH, Liu J-S, Kang SH, Singh R, Park SK, Su Y, et al. (2008) GMP production and characterization of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv (UCHT1) for phase I/II clinical trials. Protein Expr. Purif. 58(1), 1-11.
96. Su H, Jack M, McIntosh LM, PerdomoL, ChoyBSF, FinckBK, et al. (2009) Clinical grade production and characterization of a fusion protein comprised of the chemokine CCL2-ligand genetically fused to a mutated and truncated form of the Shiga A1 subunit. Protein Expr. Purif. 66(2), 149-157.
97. Mohlmann S, Bringmann P, Greven S, Harrenga A. (2011) Site-specific modification of ED-B-targeting antibody using intein-fusion technology. BMC Biotechnol. 11, 76.
98. Premsukh A, Lavoie JM, Cizeau J, Entwistle J,MacDonald GC. (2011) Development of a GMP Phase III purification process for VB4-845, an immunotoxin expressed in E. coli using high cell density fermentation. Protein Expr. Purif. 78(1), 27-37.
99. Omasa T, Onitsuka M, Kim W-D. (2010) Cell engineering and cultivation of Chinese hamster ovary (CHO) cells. Curr. Pharm. Biotechnol. 11(3), 233-240.
100. Barnes LM, Dickson AJ. (2006) Mammalian cell factories for efficient and stable protein expression. Curr. Opin. Biotechnol. 17(4), 381-386.
101. Matasci M, Hacker DL, Baldi L, Wurm FM. (2008) Recombinant therapeutic protein production in cultivated mammalian cells: current status and future prospects. DDT 5(2-3), e37-e42.
102. Lim Y,Wong NSC, Lee YY, Ku SCY,Wong DCF, Yap MGS. (2010) Engineering mammalian cells in bioprocessing- current achievements and future perspectives. Biotechnol. Appl. Biochem. 55(4), 175-189.
103. Liu YY, Gordienko I, Mathias A, Ma S, Thompson J,Woo JH, et al. (2000) Expression of an anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin in a mutant CHO cell line. Protein Expr. Purif. 19(2), 304-311.
104. Grillberger L, Kreil TR, Nasr S, Reiter M. (2009) Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol. J. 4(2), 186-201.
105. Qian Y, Jing Y, Li ZJ. (2010) Glucocorticoid receptor-mediated reduction of IgG-fusion protein aggregation in Chinese hamster ovary cells. Biotechnol. Prog. 26(5), 1417-1423.
106. Boado RJ, Hui EK-W, Lu JZ, Pardridge WM. (2011) CHO cell expression, long-term stability, and primate pharmacokinetics and brain uptake of an IgG-paroxonase-1 fusion protein. Biotechnol. Bioeng. 108(1), 186-196.
107. Kalyanpur M. (2002) Downstream processing in the biotechnology industry. Mol. Biotechnol. 22(1), 87-98.
108. Balasundaram B, Harrison S, Bracewell DG. (2009) Advances in product release strategies and impact on bioprocess design. Trends Biotechnol. 27(8), 477-485.
109. Baneyx F, Mujacic M. (2004) Recombinant protein folding and misfolding in Escherichia coli. Nat. Biotechnol. 22(11), 1399-1408.
110. Fahnert B, Lilie H, Neubauer P. (2004) Inclusion bodies: formation and utilisation. Adv. Biochem. Eng. Biotechnol. 89, 93-142.
111. Hassouneh W, Christensen T, Chilkoti A. (2010) Elastin-like polypeptides as a purification tag for recombinant proteins. Curr. Protoc. Protein Sci. Chapter 6, Unit 6.11.
112. Ghose S, Hubbard B, Cramer SM. (2007) Binding capacity differences for antibodies and Fc-fusion proteins on protein A chromatographicmaterials. Biotechnol.Bioeng. 96(4), 768-779.
113. Xu X, Didio DM, Leister KJ, Ghose S. (2010) Disaggregation of high-molecular weight species during downstream processing to recover functional monomer. Biotechnol. Prog. 26(3), 717-726.
114. Roque ACA, Lowe CR, Taipa MA. (2004) Antibodies and genetically engineered related molecules: production and purification. Biotechnol. Prog. 20(3), 639-654.
115. Nilson BH, Solomon A, Bjorck L, Akerstrom B. (1992) Protein L from Peptostreptococcus magnus binds to the kappa light chain variable domain. J. Biol. Chem. 267(4), 2234-2239.
116. Pigeon C, Jackson M, Baines D. (2009) Application of FabsorbentTM F1P HF, a synthetic ligand adsorbent for capture and purification of a single-domain antibody fragment expressed in Escherichia coli. Bio. Proc. Intl. 7(7), 90-91.
117. El Khoury G, Rowe LA, Lowe CR. (2012) Biomimetic affinity ligands for immunoglobulins based on the multicomponent Ugi reaction. Methods Mol. Biol. 800, 57-74.
118. Willems A, Leoen J, Schoonooghe S, Grooten J, Mertens N. (2003) Optimizing expression and purification from cell culture medium of trispecific recombinant antibody derivatives. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 786(1-2), 161-176.
119. Lobbezoo B, Dodd R, Morton P, Duell M. (2011) A novel high performance adsorbent as a platform process for the capture & purification of albumin-fusion proteins. PREP 2011-24th International Symposium, 1.
120. (2002) Amediplase: CGP 42935, K2tu-PA, MEN 9036. Bio- Drugs 16(5), 378-379.
121. Rosa PAJ, Azevedo AM, Sommerfeld S, Backer W, Aires- Barros MR. (2011)Aqueous two-phase extraction as a platform in the biomanufacturing industry: economical and environmental sustainability. Biotechnol. Adv. 29(6), 559-567.
122. Jorgensen L, Hostrup S, Moeller EH, Grohganz H. (2009) Recent trends in stabilising peptides and proteins in pharmaceutical formulation-considerations in the choice of excipients. Expert Opin. Drug Deliv. 6(11), 1219-1230.
123. Patro SY, Freund E, Chang BS. (2002) Protein formulation and fill-finish operations. Biotechnol Annu. Rev. 8, 55-84.
124. Frokjaer S, Otzen DE. (2005) Protein drug stability: a formulation challenge. Nat. Rev. Drug Discov. 4(4), 298-306.
125. Roberts CJ, Das TK, Sahin E. (2011) Predicting solution aggregation rates for therapeutic proteins: approaches and challenges. Int. J. Pharm. 418(2), 318-333.
126. Rathore N, Rajan RS. (2008) Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol. Prog. 24(3), 504-514.
127. Haselbeck A. (2003) Epoetins: differences and their relevance to immunogenicity. Curr. Med. Res. Opin. 19(5), 430-432.
128. Sharma B. (2007) Immunogenicity of therapeutic proteins. Part 2: impact of container closures. Biotechnol. Adv. 25(3), 318-324.
129. Chang JY, Xiao NJ, Zhu M, Zhang J, Hoff E, Russell SJ, et al. (2010) Leachables from saline-containing IV bags can alter therapeutic protein properties. Pharm. Res. 27(11), 2402-2413.
130. Brown LR. (2005) Commercial challenges of protein drug delivery. Expert Opin. Drug Deliv. 2(1), 29-42.
131. Dumont JA, Low SC, Peters RT, Bitonti AJ. (2006) Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs 20(3), 151-160.
132. Jezek J, Rides M, Derham B, Moore J, Cerasoli E, Simler R, et al. (2011) Viscosity of concentrated therapeutic protein compositions. Adv. Drug Deliv. Rev. 63(13), 1107-1117.
133. Shire SJ. (2009) Formulation and manufacturability of biologics. Curr. Opin. Biotechnol. 20(6), 708-714.
134. Cordes AA, Platt CW, Carpenter JF, Randolph TW. (2012) Selective domain stabilization as a strategy to reduce fusion protein aggregation. J. Pharm. Sci. 101(4), 1400-1409.
135. Werner RG. (2004) Economic aspects of commercial manufacture of biopharmaceuticals. J. Biotechnol. 113(1-3), 171-182.
136. Lee GH, Cooney D, Middelberg APJ, Choe WS. (2006) The economics of inclusion body processing. Bioprocess Biosyst. Eng. 29(2), 73-90.
137. Ernst S, Garro OA, Winkler S, Venkataraman G, Langer R, Cooney CL, et al. (1997) Process simulation for recombinant protein production: cost estimation and sensitivity analysis for heparinase I expressed in Escherichia coli. Biotechnol. Bioeng. 53(6), 575-582.
138. Datar RV, Cartwright T, Rosen CG. (1993) Process economics of animal cell and bacterial fermentations: a case study analysis of tissue plasminogen activator. Biotechnology (NY) 11(3), 349-357.
139. Kelley B. (2009) Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs 1, 443-452.
140. Farid SS. (2007) Process economics of industrial monoclonal antibody manufacture. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci 848(1), 8-18.
141. Langer ES. (2009) Trends in capacity utilization for therapeutic monoclonal antibody production. MAbs 1(2), 151-156.
142. Novais JL, Titchener-Hooker NJ, Hoare M. (2001) Economic comparison between conventional and disposables-based technology for the production of biopharmaceuticals. Biotechnol. Bioeng. 75(2), 143-153.
143. Varadaraju H, Schneiderman S, Zhang L, Fong H, Menkhaus TJ. (2011) Process and economic evaluation for monoclonal antibody purification using a membrane-only process. Biotechnol. Prog. 27(5), 1297-1305.
144. Gottschalk U. (2008) Bioseparation in antibody manufacturing: the good, the bad and the ugly. Biotechnol. Prog. 24(3), 496-503.
145. Brooks SA. (2006) Protein glycosylation in diverse cell systems: implications for modification and analysis of recombinant proteins. Expert Rev. Proteomics 3(3), 345-359.
146. Werner RG, Kopp K, Schlueter M. (2007) Glycosylation of therapeutic proteins in different production systems. Acta Paediatr. Suppl. 96(455), 17-22.
147. Borys MC, Dalal NG, Abu-Absi NR, Khattak SF, Jing Y, Xing Z, et al. (2010) Effects of culture conditions on Nglycolylneuraminic acid (Neu5Gc) content of a recombinant fusion protein produced in CHO cells. Biotechnol. Bioeng. 105(6), 1048-1057.
148. Hooker A, James D. (1998) The glycosylation heterogeneity of recombinant human IFN-gamma. J. Interferon Cytokine Res. 18(5), 287-295.
149. Raju TS. (2008) Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr. Opin. Immunol. 20(4), 471-478.
150. Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, et al. (2011) Combined Fc-protein- and Fc-glyco-engineeringofscFv-Fcfusionproteinssynergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. J. Immunol. Methods 373(1-2), 67-78.
151. Fares FA, Suganuma N, Nishimori K, LaPolt PS, Hsueh AJ, Boime I. (1992) Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc. Natl. Acad. Sci. USA 89(10), 4304-4308.
152. Egrie JC, Browne JK. (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Br. J. Cancer 84(Suppl. 1), 3-10.
153. Sola RJ, Griebenow K. (2009) Effects of glycosylation on the stability of protein pharmaceuticals. J. Pharm. Sci. 98(4), 1223-1245.
154. Umãna P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17(2), 176-180.
155. Hamilton SR, Gerngross TU. (2007) Glycosylation engineering in yeast: the advent of fully humanized yeast. Curr. Opin. Biotechnol. 18(5), 387-392.
156. Hamilton SR, Davidson RC, Sethuraman N, Nett JH, Jiang Y, Rios S, et al. (2006) Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 313 (5792), 1441-1443.
157. Wildt S, Gerngross TU. (2005) The humanization of Nglycosylation pathways in yeast. Nat. Rev. Microbiol. 3(2), 119-128.
158. Sharma SK, Pedley RB, Bhatia J, Boxer GM, El-Emir E, Qureshi U, et al. (2005) Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. Clin. Cancer Res. 11(2 Pt 1), 814-825.
159. Schellekens H. (2005) Follow-on biologics: challenges of the "next generation." Nephrol. Dial. Transplant. 20(Suppl. 4), iv31-36.
160. Shanafelt AB. (2005) Medicinally useful proteins-enhancing the probability of technical success in the clinic. Expert Opin. Biol. Ther. 5(2), 149-151.
161. Rathore AS. (2009) Follow-on protein products: scientific issues, developments and challenges. Trends Biotechnol. 27(12), 698-705.
162. Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L, Christ D. (2011) Aggregation, stability, and formulation of human antibody therapeutics. In: Advances in Protein Chemistry and Structural Biology, Academic Press, 41-61.
163. Baumann A. (2009) Nonclinical development of biopharmaceuticals. Drug Discov. Today 14(23-24), 1112-1122.
164. Dixit R, Boelsterli UA. (2007) Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies. Drug Discov. Today 12(7-8), 336-342.
165. Bussiere JL, Martin P, Horner M, Couch J, Flaherty M, Andrews L, et al. (2009) Alternative strategies for toxicity testing of species-specific biopharmaceuticals. Int. J. Toxicol. 28(3), 230-253.
166. Chen X, Lee H-F, Zaro JL, Shen W-C. (2011) Effects of receptor binding on plasma half-life of bifunctional transferrin fusion proteins. Mol. Pharm. 8(2), 457-465.
167. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. (2010) The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov. 9(4), 325-338.
168. Roberts SA, Woodnutt G, Bradshaw CW, Gad SC. (2010) Strategy considerations for developing the preclinical safety testing programs for protein scaffold therapeutics. In: Pharmaceutical Sciences Encyclopedia. John Wiley & Sons, Inc., pp. 1-16.
169. Beck A, Reichert JM. (2011) Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 3(5), 415-416.
170. Bokemeyer C. (2010) Catumaxomab-trifunctional anti- EpCAM antibody used to treat malignant ascites. Expert Opin. Biol. Ther. 10(8), 1259-1269.
171. Hiller A. (2009) Fast growth foreseen for protein therapeutics. GEN 29(1), 153-155.
172. Langlands B. (2011) Next-generation protein and peptide therapeutics. Scrip Bus. Insights 1-192.